MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Cancer Immunotherapy and Biomarkers
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,980 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,980 works in the cohort · of 4,299,418page 44 of 60

Labels cover 12 of 2,980 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,980 of 2,980 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
AN UNSUSPECTED CASE OF MYOCARDITIS ASSOCIATED WITH NIVOLUMAB USE
Hussain Alzayer, Hassan Mir, Ahmad Alshatti, Nicholas Valettas, Som D. Mukherjee, Darryl P. Leong
2017· article· en· Journal of the American College of Cardiology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Immune Checkpoint Inhibitors
Keith C.K. Lau, R. Benson Weyant, Carlos Cervera
2022· book-chapter· en· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Ipilimumab
Anand Rotte, Madhuri Bhandaru
2016· book-chapter· en· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Nivolumab
Anand Rotte, Madhuri Bhandaru
2016· book-chapter· fr· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
fundno affno abstractunlabeled
641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Johann S. de Bono, Neal D. Shore, Gero Kramer, Anthony M. Joshua, X.T. Li, Christian Poehlein +2 more
2021· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Literature on target therapy of malignant melanoma.
Mohammad Ali Esmaeil Pour, Mahsa Mohebtash, Ali Amin, Azadeh Khayyat, Amir-Reza Khalili-Toosi, Mengni Guo +2 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About